Unable to attend this year’s

ECCO Congress 2016?

View the full-length webcasts of 2 Takeda-sponsored symposia

In It
for the
Long Haul

Managing the
Complexity of
Crohn's Disease

Saturday, 19 March 2016
07:15 - 08-15

Plenary Hall
RAI Amsterdam
The Netherlands

Speaker Biographies

Michael A. Kamm, MD, PhD

St Vincent's Hospital Melbourne
Victoria, Australia

Michael A. Kamm, MD, PhD, is Professor of Gastroenterology at St Vincent's Hospital Melbourne, the University of Melbourne, Victoria, Australia, and Imperial College London, UK. Dr Kamm's clinical work covers the spectrum of luminal gastroenterology, with a special interest in inflammatory bowel disease (IBD), neuromuscular disorders of the gut and pelvic floor, and functional gut disorders. He spends half his time in clinical practice, and half in research and teaching. Dr Kamm's research spans from basic science to the clinical aspects of intestinal and pelvic floor diseases.

Dr Kamm has been on the editorial boards of several national and international journals. He lectures and publishes widely. Dr Kamm has served on a number of government, charitable, and industry advisory boards. His research has been recognized by awards in Australia, Asia, South Africa, Sweden, UK, and USA.

Remo Panaccione, MD

Director, Inflammatory Bowel Disease Clinic
Associate Professor of Medicine
University of Calgary
Alberta, Canada

Remo Panaccione, MD, is currently Associate Professor of Medicine and Director of the Inflammatory Bowel Disease Clinic at the University of Calgary, Alberta, Canada.

Dr Panaccione received his MD from the University of Western Ontario, London, Canada in 1993. He went on to complete his internal medicine and gastroenterology training at that institution, and is certified as a Fellow of the Royal College of Physicians and Surgeons of Canada in both areas. Dr Panaccione completed advanced training in IBD at the Mayo Clinic, Rochester, Minnesota, USA. He joined the Faculty of Medicine of the University of Calgary in 1999.

Dr Panaccione has lectured across North America on various topics in IBD and has delivered over 120 lectures in the last 5 years. He is the author of many peer-reviewed articles and book chapters on IBD. His special interest lies in the fields of advanced immunomodulation and biologic therapy. Dr Panaccione is a recognized authority on the use of infliximab in Canada and co-authored guidelines on the use of this agent for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in CD and ulcerative colitis. Dr Panaccione is currently Medical Director of the Calgary chapter of Crohn's and Colitis Foundation Canada and serves on the Medical Advisory Council of the parent organization.

Dr Panaccione has a great interest in medical education. He has been recognized as a Gold Star Lecturer, Small Groups Leader, and Clinical Preceptor by the University of Calgary Cumming School of Medicine. Dr Panaccione has been selected as the top postgraduate teacher in gastroenterology by the gastroenterology fellows of the university 3 times. Most recently, he was selected as one of the institution's "greatest teachers" (http://greatteachers.ucalgary.ca).

Stefan Schreiber, MD

Professor of Medicine
Institute for Clinical Molecular Biology
University Hospital Schleswig-Holstein
Kiel, Germany

Stefan Schreiber, MD, was born in 1962 and received his MD in 1988 from the University of Hamburg, Germany. Prof Schreiber is a certificated internist and gastroenterologist. Following a postdoctoral research fellowship in the Depts of Gastroenterology at Washington University in St. Louis, Missouri, USA, and the University of Pennsylvania, Philadelphia, USA, he became a junior faculty member in the Dept of Gastroenterology at Charité–Universitätsmedizin Berlin, Germany. In 1996, Prof Schreiber assumed the position of Associate Professor in the Clinic for Internal Medicine I at Christian-Albrechts-Universität, Kiel, Germany.

Prof Schreiber´s present position is Full Professor of Medicine at Christian-Albrechts-Universität, where he also serves as Director of the Clinic of Internal Medicine I and Head of the Institute for Clinical Molecular Biology. Moreover, he is Speaker of the German Research Foundation-funded Cluster of Excellence "Inflammation-at-Interfaces."

Prof Schreiber´s research interests include the molecular genetics and pathophysiology of chronic intestinal inflammation, clinical development of new therapies for IBD, and discovery of mechanisms that control aging. He is a member of several professional societies, including the American Gastroenterological Association, European Society for Clinical Investigation, German Crohn's Disease/Ulcerative Colitis Foundation (Scientific Committee), German Society of Internal Medicine, and German Society for Gastroenterology, Digestive and Metabolic Diseases. Prof Schreiber has been an invited lecturer, and held chairmanships at multiple national and international meetings. He is joint editor of several international journals in IBD and genetics, and has authored more than 800 original publications in various scientific journals.